Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Japan; Rockville, MD; and Epalinges, Switzerland – January 6, 2014 – Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic...
Tokyo, December 25, 2013 - Astellas Pharma Inc. (“Astellas”) and Immuno-Biological Laboratories Co., Ltd. (“IBL”) today announced that they have concluded a collaborative research...
Tokyo, December 20, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) announced the approval of an additional indication for hypnosedative,...
Read more about Approval of Additional Indication for Hypnosedative, Dormicum® in Japan
Tokyo, December 13, 2013 – Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that it completed acquisition of its...
Read more about Notice of Completion of Acquisition of Own Shares
Tokyo, December 13, 2013 - Astellas Pharma Inc. (“Astellas”; headquarters : Tokyo:4503; President and CEO: Yoshihiko Hatanaka), today announced that a definitive agreement has been concluded...
Follow us
